Page last updated: 2024-08-17

prednisone and pyrazines

prednisone has been researched along with pyrazines in 123 studies

Research

Studies (123)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	41 (33.33)	29.6817
2010's	82 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jäger, U	1
Tang, X	1
Hajek, R; Krejci, M; Krivanova, A; Pour, L; Vorlicek, J; Zdenek, A	1
Kyle, RA; Vincent Rajkumar, S	1
Bohlius, J; Engert, A; Hülsewede, H; Kober, T	1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H	1
Heule, F; Lam, K; Sonneveld, P; Wu, KL	1
Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P	1
Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O	1
Fassas, AB; Tricot, G	1
Hatake, K; Terui, Y; Yokoyama, M	1
Eicher, C; Heller, G; Kelly, WK; Morris, MJ; Ryan, C; Scher, HI; Slovin, S	1
Ganser, A; Peest, D	1
Faiman, B	1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H	1
Chrysanthopoulou, H; Dimopoulos, MA; Kastritis, E; Matsouka, C; Michopoulos, S; Petraki, K	1
Facon, T; Hulin, C; Moreau, P	2
Bazarbachi, A; Hatoum, HA; Mahfouz, RA; Otrock, ZK; Salem, ZM; Tawil, A; Zaatari, GS	1
Chen, C; Kukreti, V; Mikhael, J; Pantoja, M; Reece, DE; Rodriguez, GP; Stewart, AK; Trudel, S; Xu, W	1
Eom, HS; Huh, J; Kang, HJ; Kim, K; Kim, WS; Ko, YH; Lee, J; Park, K; Ryoo, BY; Suh, C	1
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H	1
Durie, BG	1
Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A	1
Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S	1
Bladé, J; Rosiñol, L	1
Cheson, BD	1
Ambrus, JL; Islam, A	1
Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C	1
Kami, M; Komatsu, T; Tsubokura, M	1
Avvisati, G	1
García-Bustínduy, M; Martín-Herrera, A; Noda-Cabrera, A; Rodríguez-Martín, M; Sáez-Rodríguez, M	1
Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A	1
Berenson, JR	1
Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L	1
Brice, P; Briere, J; Ertault, M; Ferme, C; Gisselbrecht, C; Golfier, JB; Haioun, C; Mounier, N; Ribrag, V; Salles, G	1
Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H	1
Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM	1
Beguin, Y; Bonnet, C; de Leval, L; Deprijck, B; Fillet, G	1
Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H	1
Azaïs, I; Brault, R; Debiais, F	1
Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F	1
Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H	1
Colby, TV; Fonseca, R; Khan, ML; Viggiano, RW	1
Everly, MJ; Jahr, F; Kaneku, H; Terasaki, PI; Trivedi, HL	1
Lonial, S	1
Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H	1
Cheung, YK; Coleman, M; Elstrom, R; Furman, RR; LaCasce, AS; Leonard, JP; Martin, P; Ruan, J; Vose, JM	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB	1
Rajkumar, SV	2
Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D	1
Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL	1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D	1
Palumbo, A	1
Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K	1
Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM	1
Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S	1
Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z	1
Mateos, MV; San-Miguel, J	1
Schots, R	1
Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H	1
Kyle, RA; Steensma, DP	1
Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M	1
Basi, S; Cantin, G; Chen, BE; Couban, S; Crump, M; Djurfeldt, M; Gascoyne, RD; Imrie, K; Lemieux, B; MacDonald, D; Rubin, S; Rubinger, M; Sehn, LH; Shepherd, L; Sussman, J	1
Campo, E; Colomer, D; Jares, P; López-Guillermo, A; Martinez, A; Mozos, A; Roué, G	1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I	1
D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O	1
Brandt, S; Chinratanalab, W; Englehardt, B; Goodman, S; Greer, JP; Jagasia, MH; Kassim, A; Morgan, DS; Oluwole, O; Reddy, N; Savani, BN	1
Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL	1
Cakana, A; Delforge, M; Dhawan, R; Esseltine, DL; Meunier, J; Regnault, A; Richardson, PG; Robinson, D; San Miguel, JF; van de Velde, H	1
Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T	1
Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M	1
Chigira, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shirane, S; Sugimoto, K; Wakabayashi, M	1
Charliński, G; Jedrzejczak, WW; Wiater, E	1
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E	1
Do, IG; Huh, J; Kang, HJ; Kim, HJ; Kim, HK; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, SS; Min, SK; Park, SK; Ryoo, BY; Suh, C; Yang, WI; Yoon, DH	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; García-Sanz, R; González, Y; Granell, M; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Oriol, A; Palomera, L; Peñalver, FJ; Pérez, M; Polo, M; Ribera, JM; San-Miguel, JF; Teruel, AI	1
Harousseau, JL	1
Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A	1
Mahé, E; Sigal, ML; Sin, C	1
Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T	1
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H	1
Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST	1
Lonial, S; Miguel, JF	1
Mina, R; Palumbo, A	1
Bagot, M; Bezier, M; Cordoliani, F; Delyon, J; Malphettes, M; Rybojad, M; Szalat, R	1
Collet, P; Marotte, H; Nizeica, V	1
Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N	1
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A	1
Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M	1
Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L	1
Drach, J; Drach-Schauer, B; Eder, S; Lamm, W	1
Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S	1
Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R	1
Alloway, RR; Cardi, MA; Krisl, JC; Shields, AR; Woodle, ES	1
Adam, Z; Krejčí, M; Pour, L; Ševčíková, E	1
Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H	1
Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT	1
Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H	1
Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T	1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ	1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A	1
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G	1
Cabanillas, F; Chen, CS; Craig, M; Esseltine, DL; Hanna, WT; Neuwirth, R; O'Connor, OA	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI	1
Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J	1
Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK	1
Furtado, M; Johnson, R; Kruger, A; Rule, S; Turner, D	1
Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H	1
Tsurumi, H	1
Abenhardt, W; Aldaoud, A; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Münz, M; Nusch, A	1
Brown, RE; Nguyen, ND; Quesada, AE; Rios, A	1
Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H	1
Castillo, JJ; Reagan, JL; Sikov, WM; Winer, ES	1
Alexeeva, J; Cavalli, F; Drach, J; Hong, X; Huang, H; Jin, J; Liu, T; Mayer, J; Okamoto, R; Osmanov, E; Pei, L; Pereira, J; Pylypenko, H; Robak, T; Rooney, B; Samoilova, O; Siritanaratkul, N; van de Velde, H; Verhoef, G; Zhu, J	1
Ishida, T	1
Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK	1
Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W	1
Carlson, RD; Crozier, I; Debiec, MR; Hill, CE; Kraft, CS; Kumar, G; Lyon, GM; Martin, DF; Mehta, AK; Nussenblatt, RB; Olsen, TW; Patel, PS; Ribner, BS; Shantha, JG; Smith, JR; Ströher, U; Uyeki, TM; Varkey, JB; Yeh, S	1
Appleby, N; Boucher, R; Cabes, M; Eyre, TA; Fox, S; Hillmen, P; Jackson, A; Rawstron, A; Schuh, A; Yates, F	1

Reviews

22 review(s) available for prednisone and pyrazines

Article	Year
Treatment of multiple myeloma: an emphasis on new developments. Annals of medicine, 2006, Volume: 38, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2006
Fourth biannual report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine	2006
Tandem transplants in the treatment of multiple myeloma. Pro. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2004
[Recent progress in rituximab therapy and its resistance--how do we overcome?]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CD55 Antigens; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Point Mutation; Prednisone; Pyrazines; Rituximab; Vincristine	2007
[Therapy of multiple myeloma: indications and options]. Der Internist, 2007, Volume: 48, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden	2007
Clinical updates and nursing considerations for patients with multiple myeloma. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome	2007
Frontline treatment of multiple myeloma in elderly patients. Blood reviews, 2008, Volume: 22, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide	2008
Advances in therapy of multiple myeloma. Current opinion in oncology, 2008, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome	2008
[Current treatment of follicular lymphoma]. Revue medicale suisse, 2009, Aug-26, Volume: 5, Issue:214 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Prednisone; Prognosis; Pyrazines; Radioimmunotherapy; Radiotherapy, Adjuvant; Risk Factors; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine	2009
New treatments for myeloma. Joint bone spine, 2010, Volume: 77, Issue:1 Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide	2010
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. American journal of hematology, 2011, Volume: 86, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2011
Treatment of newly diagnosed myeloma in patients not eligible for transplantation. Current hematologic malignancy reports, 2011, Volume: 6, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2011
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2011
Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert review of hematology, 2012, Volume: 5, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide	2012
Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:11 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Boronic Acids; Bortezomib; Fatal Outcome; Humans; Leukemia, Plasma Cell; Male; Melphalan; Pleural Effusion, Malignant; Prednisone; Pyrazines; Treatment Failure	2012
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome	2012
Induction therapy for newly diagnosed multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2013
Part II: role of maintenance therapy in transplant-ineligible patients. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine	2013
[Therapy of Waldenström´s macroglobulinaemia in the year 2014]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:2 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia	2014
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2014
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine	2014
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide	2014

Trials

41 trial(s) available for prednisone and pyrazines

Article	Year
[Effect of ligustrazine on proliferative glomerulonephritis]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2003, Volume: 26, Issue:8 Topics: Adolescent; Adult; Creatinine; Cyclophosphamide; Dipyridamole; Drug Therapy, Combination; Female; Fibrinolytic Agents; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Humans; Losartan; Male; Middle Aged; Prednisone; Pyrazines; Serum Albumin	2003
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 2006, Oct-01, Volume: 108, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease-Free Survival; Humans; Immunophenotyping; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines	2006
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 2007, Apr-01, Volume: 109, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide	2007
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. The Journal of urology, 2007, Volume: 178, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Risk Assessment; Survival Rate; Treatment Outcome	2007
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica, 2008, Volume: 93, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis	2008
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis	2008
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proteasome Endopeptidase Complex; Pyrazines; Vincristine	2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome	2008
Update on recent developments for patients with newly diagnosed multiple myeloma. Annals of the New York Academy of Sciences, 2008, Volume: 1138 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2008
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer, 2009, Oct-01, Volume: 115, Issue:19 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine	2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome	2010
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-20, Volume: 27, Issue:36 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome	2009
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome	2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States	2010
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood, 2010, Nov-11, Volume: 116, Issue:19 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Remission Induction; Time Factors; Treatment Outcome	2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer, 2010, Dec-01, Volume: 116, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine	2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom The Lancet. Oncology, 2010, Volume: 11, Issue:10 Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European journal of haematology, 2011, Volume: 86, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors	2011
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome	2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-20, Volume: 29, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Treatment Outcome; Vincristine; Young Adult	2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome	2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. European journal of haematology, 2011, Volume: 86, Issue:5 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant	2011
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-01, Volume: 29, Issue:25 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Cyclophosphamide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Pyrazines; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vincristine	2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood, 2011, Nov-24, Volume: 118, Issue:22 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome	2011
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. European journal of haematology, 2012, Volume: 89, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Quality of Life; Treatment Outcome	2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer, 2012, Jul-15, Volume: 118, Issue:14 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neural Conduction; Prednisone; Pyrazines; Rituximab; Vincristine	2012
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Prednisone; Pyrazines; Vincristine	2012
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood, 2012, Sep-27, Volume: 120, Issue:13 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Maintenance Chemotherapy; Male; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide	2012
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study. Cancer, 2013, Mar-01, Volume: 119, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence	2013
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-01, Volume: 31, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neoplasms, Second Primary; Odds Ratio; Prednisone; Proportional Hazards Models; Pyrazines; Risk; Spain; Treatment Outcome	2013
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome	2014
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. European journal of haematology, 2014, Volume: 93, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome	2014
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood, 2014, Jun-26, Volume: 123, Issue:26 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate	2014
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines	2014
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. British journal of haematology, 2014, Volume: 166, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome	2014
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood, 2014, Sep-18, Volume: 124, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2014
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. British journal of haematology, 2015, Volume: 168, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Pyrazines; Treatment Outcome; Vincristine	2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. American journal of hematology, 2015, Volume: 90, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis	2015
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. The New England journal of medicine, 2015, Mar-05, Volume: 372, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine	2015
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in BMC cancer, 2019, May-20, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prospective Studies; Pyrazines; Recurrence; Research Design; Rituximab; Treatment Outcome; Vincristine; Young Adult	2019

Other Studies

60 other study(ies) available for prednisone and pyrazines

Article	Year
Innovative strategies in lymphoma therapy. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine	2003
Skin lesions induced by bortezomib. Haematologica, 2005, Volume: 90, Issue:12 Suppl Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cetirizine; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Exanthema; Histamine H1 Antagonists, Non-Sedating; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Salvage Therapy	2005
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:5 Topics: Adult; Aged; Boronic Acids; Bortezomib; Drug Eruptions; Drug Therapy, Combination; Erythema; Fever; Glucocorticoids; Histamine H1 Antagonists; Humans; Male; Medical Records; Middle Aged; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Skin; Skin Ulcer	2006
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 2007, Volume: 21, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes	2007
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2007
Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Immunohistochemistry; Lymphoma, Mantle-Cell; Male; Prednisone; Prognosis; Pyrazines; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine	2008
Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation. Annals of hematology, 2008, Volume: 87, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; T-Lymphocyte Subsets; Transplantation, Autologous; Vincristine	2008
Treatment of myeloma--are we making progress? The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines	2008
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma. Leukemia research, 2009, Volume: 33, Issue:4 Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation	2009
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine	2008
Bortezomib plus melphalan and prednisone for multiple myeloma. The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2008
New evidence in oncologic and cardiocirculatory medicine. Internal and emergency medicine, 2009, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines	2009
Bortezomib plus melphalan and prednisone for multiple myeloma. The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate	2008
Bortezomib plus melphalan and prednisone for multiple myeloma. The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide	2008
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report. Dermatology online journal, 2008, Nov-15, Volume: 14, Issue:11 Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Eruptions; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Salvage Therapy; Vincristine	2008
Cutaneous involvement in multiple myeloma and bortezomib. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia	2009
Hematology: Bortezomib in newly diagnosed multiple myeloma. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome	2009
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone. Leukemia research, 2009, Volume: 33, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine	2009
Successful bortezomib-based treatment in POEMS syndrome. European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine	2009
Treatment of multiple myeloma: 2009 update. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine	2009
Treatment with bortezomib of a patient having hyper IgG4 disease. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:3 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Eyelid Diseases; Female; Humans; Immune System Diseases; Immunoglobulin G; Middle Aged; Plasma Cell Granuloma, Pulmonary; Prednisone; Pyrazines; Tomography, X-Ray Computed	2010
Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol. Clinical transplants, 2009 Topics: Adrenal Cortex Hormones; Adult; Biopsy; Boronic Acids; Bortezomib; Clonal Deletion; Creatinine; Follow-Up Studies; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; India; Kidney Transplantation; Living Donors; Prednisone; Protease Inhibitors; Pyrazines; Young Adult	2009
Frontline regimens for multiple myeloma patients. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2010
Optimising bortezomib in newly diagnosed multiple myeloma. The Lancet. Oncology, 2010, Volume: 11, Issue:10 Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome	2010
First-line treatment of elderly multiple myeloma patients. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2010
De novo AL amyloidosis in the kidney allograft. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011, Volume: 11, Issue:3 Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome	2011
Recent advances in myeloma treatment. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2011, Volume: 44, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide	2011
History of multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane	2011
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. The American journal of pathology, 2011, Volume: 179, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Protease Inhibitors; Pyrazines; Receptors, Neuropeptide; RNA, Messenger; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vincristine; Young Adult	2011
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine	2012
Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Experimental hematology, 2012, Volume: 40, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine	2012
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting	2012
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:190 Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide	2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia, 2013, Volume: 27, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine	2013
How to select among available options for the treatment of multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2012
Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin. Diabetes & metabolism, 2012, Volume: 38, Issue:6 Topics: Acute Kidney Injury; Aged; Back; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ear; Edema; Eosinophilia; Exanthema; Female; Glucocorticoids; Humans; Prednisone; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies	2013
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan The oncologist, 2013, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States	2013
[Cutaneous manifestations revealing cryofibrinogenaemia associated with monoclonal gammopathy]. Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:1 Topics: Acute Kidney Injury; Adult; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Cryoglobulinemia; Cryoglobulins; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Fibrinogens, Abnormal; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Kidney; Leg Ulcer; Microscopy, Fluorescence; Necrosis; Paraproteinemias; Plasmapheresis; Prednisone; Pyrazines; Skin	2013
Bortezomib induced a phrenic palsy in a multiple myeloma patient. Annals of hematology, 2013, Volume: 92, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid	2013
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine	2013
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma. British journal of haematology, 2013, Volume: 162, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy	2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leukemia research, 2013, Volume: 37, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult	2013
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies	2013
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology, 2013, Volume: 85, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome	2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. American journal of hematology, 2014, Volume: 89, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome	2014
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept. Transplantation, 2014, Feb-27, Volume: 97, Issue:4 Topics: Abatacept; Adult; Azathioprine; Biopsy; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Cyclosporine; Glomerulonephritis, IGA; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Male; Prednisone; Pyrazines; Treatment Outcome	2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica, 2014, Volume: 99, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome	2014
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome	2014
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine	2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide	2014
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine	2014
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. Genes, chromosomes & cancer, 2015, Volume: 54, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; DNA Copy Number Variations; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prednisone; Pyrazines	2015
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncology research and treatment, 2014, Volume: 37, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Germany; Glucocorticoids; Hematology; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Pyrazines; Registries	2014
Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14 Suppl Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; NF-kappa B; Positron-Emission Tomography; Prednisone; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Vincristine	2014
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. British journal of haematology, 2015, Volume: 169, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Treatment Outcome; Vincristine	2015
[Complications and managements in treatment of melphalan, prednisone and new agents]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide	2015
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. Acta haematologica, 2015, Volume: 134, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide	2015
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases. American journal of hematology, 2015, Volume: 90, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis	2015
Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor. Ophthalmology, 2016, Volume: 123, Issue:12 Topics: Administration, Oral; Adult; Amides; Atropine; Drug Combinations; Ebolavirus; Eye Infections, Viral; Fluprednisolone; Glucocorticoids; Hemorrhagic Fever, Ebola; Humans; Injections, Intraocular; Iris Diseases; Male; Microscopy, Acoustic; Multimodal Imaging; Mydriatics; Ophthalmic Solutions; Panuveitis; Pigmentation Disorders; Prednisone; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Viral; Survivors; Triamcinolone Acetonide; Vitreous Body	2016